ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of ...
Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...
Biotechnology company Bracco Imaging announced its expansion into the cell-therapy manufacturing space, establishing a new ...
Aptevo Therapeutics Inc. has added a preclinical candidate, APVO-455, to its portfolio of CD3-directed candidates built on the CRIS-7-derived CD3 binding domain.
New findings reveal how cancer manipulates immune pathways and highlight therapeutic strategies to unleash T-cells against even the most resistant tumors. Study: Cancer cells impair monocyte-mediated ...
In a recent study published in the journal Nature, researchers from the United States of America developed the synthetic intramembrane proteolysis receptor (SNIPR) architecture to activate engineered ...
AZoLifeSciences on MSN
Engineered CD4 CAR T cells reduce amyloid plaques in Alzheimer’s
Findings suggest engineered CD4+ T cells can modify Alzheimer's pathology and improve CNS immune responses, highlighting a novel therapeutic approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results